Clinical trials: Shock, Hemorrhagic, open to volunteers
Crohn Disease, Ulcerative Colitis
Safety and Efficacy of Fecal Microbiota Transplantation
The gut microbiota is critical to health and functions with a level of complexity comparable to that of an organ system. Dysbiosis, or alterations of this gut microbiota ecology, have been implicated in a number of disease…
- Conditions
- Crohn Disease, Ulcerative Colitis, Celiac Disease, Irritable Bowel Syndrome
- Trial name
- NCT04014413
- Testing
- Fecal Microbiota Transplantation
- Where
- Hong Kong
- Volunteers
- 450 people
- Sponsor
- Chinese University of Hong Kong
Trauma and Emergency Care, Shock,Hemorrhagic
Delayed Fluids in Hemorrhagic Shock Due to Severe Injuries.
This study will provide information on the quality of care in hemorrhagic shock of severe injuries in a limited resource facility of Latin America, the strategies of fluid resuscitation, and outcomes.
- Conditions
- Trauma and Emergency Care, Shock,Hemorrhagic, Intravenous Fluid Therapy
- Trial name
- PERMIT-LATAM (NCT07530653)
- Testing
- Crystalloid below 1000 mL., IV fluids more than 1,000 mL
- Where
- Colombia
- Volunteers
- 716 people
- Sponsor
- Hospital Departamental de Villavicencio
Disseminated Intravascular Coagulation (DIC), Reanimation
EARLY DIAGNOSIS OF SEPTIC DIC
Disseminated Intravascular Coagulation is a severe complication of septic shock, associated with high mortality, whose diagnosis relies on complex scores that are rarely used in practice.
- Conditions
- Disseminated Intravascular Coagulation (DIC), Reanimation, Septic Shock
- Trial name
- EASY-DIC (NCT07630415)
- Where
- France
- Volunteers
- 492 people
- Sponsor
- University Hospital, Strasbourg, France
Hypofibrinogenemia, Hemorrhage
Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated Hemorrhage
The objective of this multicenter, single-arm, observational study is to determine the feasibility and effectiveness of early administration of FDA-approved, pre-thawed Pathogen Reduced Cryoprecipitated Fibrinogen Complex…
- Conditions
- Hypofibrinogenemia, Hemorrhage, Trauma Associated Hemorrhage, Hemorrhagic Shock
- Trial name
- CRYO-FIRST (NCT07218185)
- Testing
- Pathogen Reduced Cryoprecipitated Fibrinogen Complex
- Where
- 4 sites in United States
- Volunteers
- 320 people
- Sponsor
- Cerus Corporation
Hemorrhagic Shock, Trauma
REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam
The purpose of this study is to demonstrate safety, effectiveness and benefit-risk profile of ResQFoam for the inhospital treatment of exsanguinating, intraabdominal haemorrhage due to trauma in patients where emergent laparotomy…
- Conditions
- Hemorrhagic Shock, Trauma, Exsanguinating Hemorrhage, Shock; Traumatic
- Trial name
- REVIVE (NCT02880163)
- Testing
- ResQFoam
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Arsenal Medical, Inc.
Trauma Coagulopathy, Hemorrhage
The Safety of Simplified Tranexamic Acid Regimen
Trauma causes at least 5.8 million deaths worldwide annually, accounting for 1 in 10 of all global deaths. Uncontrolled bleeding within 24 hours after trauma is the leading cause of death in trauma patients, and about one-third…
- Trial name
- NCT07869537
- Testing
- Tranexamic Acid (TXA)
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Trauma, Trauma Injury
Whole Blood in Trauma Patients With Hemorrhagic Shock
This study aims to evaluate among trauma patients with hemorrhagic shock the clinical impact of hemostatic resuscitation between whole blood vs.
- Conditions
- Trauma, Trauma Injury, Trauma, Multiple
- Trial name
- WEBSTER (NCT05634109)
- Testing
- Transfusion of blood products
- Where
- Colombia
- Volunteers
- 220 people
- Sponsor
- Fundacion Clinica Valle del Lili
Refractory Multiple Myeloma
Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
A phase II study of single agent elranatamab in patients with relapsed and/or refractory multiple myeloma (MM) who have previously received at least three classes of therapeutic agents and are refractory to the last line of…
- Trial name
- EMBRACE (NCT06421675)
- Testing
- Elranatamab injection
- Where
- 6 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Hemorrhagic Shock, Trauma
Inferior Vena Cava Versus Subclavian Vein Collapsibility for Predicting Fluid Responsiveness in Trauma Hemorrhagic Shock
Hemorrhagic shock from severe bleeding is a leading cause of preventable death in trauma patients. Intravenous (IV) fluid resuscitation is essential for stabilizing blood pressure and organ perfusion, but administering too much…
- Conditions
- Hemorrhagic Shock, Trauma, Hypovolemia, Fluid Responsiveness
- Trial name
- NCT07817966
- Volunteers
- 120 people
- Sponsor
- Assiut University
Traumatic Haemorrhagic Shock, AKI (Acute Kidney Injury) Due to Trauma
Renal Perfusion and the Development of AKI Following Traumatic Injury
Acute kidney injury (AKI) is a complication of traumatic haemorrhagic shock (THS) and together these conditions increase mortality risk.
- Conditions
- Traumatic Haemorrhagic Shock, AKI (Acute Kidney Injury) Due to Trauma, AKI - Acute Kidney Injury
- Trial name
- PERTAKI (NCT06917053)
- Testing
- Ultrasound (including contrast enhanced ultrasound), Sublingual incident dark field videomicroscopy, Urinary oxygen tension.
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- King's College Hospital NHS Trust
Shock, Shock, Septic
Early Initiated Vasopressor Therapy in the Emergency Department
The goal of this pragmatic, multi-center, superiority, randomized clinical trial is to compare early treatment with peripheral (through a vein) infused noradrenaline (a natural hormone that increases blood pressure) with fluid…
- Conditions
- Shock, Shock, Septic, Hypotension, Hypotension and Shock
- Trial name
- VASOSHOCK (NCT05931601)
- Testing
- Noradrenaline
- Where
- 8 sites in Denmark, Sweden
- Volunteers
- 320 people
- Sponsor
- Odense University Hospital
Septic Shock, Coagulopathy
Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulopathy
Sepsis-induced disseminated intravascular coagulation (DIC) is a severe complication occurring in one-third of patients with septic shock, for which no specific treatment currently exists.
- Trial name
- SivelSep (NCT07214103)
- Testing
- • Sivelestat intravenous infusion, NaCl intravenous infusion
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Strasbourg, France
Abdominal Injuries, Wounds and Injuries
Predictors of In-Hospital Mortality in Severe Abdominal Trauma
Severe abdominal trauma is a leading cause of early death from bleeding and of later death from sepsis and organ failure. Clinicians use scoring systems to estimate the risk of dying, but most of these scores were developed and…
- Conditions
- Abdominal Injuries, Wounds and Injuries, Wounds, Nonpenetrating, Wounds, Penetrating
- Trial name
- NCT07843628
- Where
- Egypt
- Volunteers
- 430 people
- Sponsor
- Minia University
Hemorrhagic Shock, Trauma Injury
Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children
The MATIC-2 is a multicenter clinical trial enrolling children who are less than 18 years of age with hemorrhagic shock potentially needing significant blood transfusion.
- Trial name
- MATIC-2 (NCT06070350)
- Testing
- Low Titer Group O Whole Blood (LTOWB), Tranexamic Acid (TXA), Component Therapy (CT)
- Where
- 23 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Philip Spinella
Hemorrhagic Shock, Pediatric Trauma
Effect of Resuscitation on Gastric Emptying Using POCUS in Pediatric Trauma Patients
Pediatric trauma often leads to hemorrhagic shock, which reduces blood flow to the digestive tract and delays gastric emptying. This delay can cause fluid and food to remain in the stomach, increasing the risk of pulmonary…
- Conditions
- Hemorrhagic Shock, Pediatric Trauma, Delayed Gastric Emptying, Gastric Dysmotility
- Trial name
- NCT07810907
- Volunteers
- 50 people
- Sponsor
- Assiut University
Acute Kidney Injury
Comparison of Early Proton Pump Inhibitor Initiation Versus Usual Care on Acute Kidney Injury in Hemorrhagic Shock Patients
The investigators propose a single-center, randomized, controlled trial to determine whether early initiation of proton pump inhibitor (PPI), pantoprazole, will decrease acute kidney injury (AKI) for trauma patients presenting…
- Trial name
- Trauma AKI PPI (NCT06531642)
- Testing
- Protonix (Pantoprazole) 40 mg q 12 hrs for 2 days, Protonix (pantoprazole) 40 mg q 24 hrs for 2 days
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Relapsed/Refractory Multiple Myeloma (RRMM)
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
This study is researching whether the use of tocilizumab before the first dose of linvoseltamab will decrease the risk of Cytokine Release Syndrome (CRS) in participants who have Relapsed or Refractory Multiple Myeloma (RRMM) who…
- Trial name
- POPLIN (NCT07609940)
- Testing
- Linvoseltamab, Tocilizumab
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Regeneron Pharmaceuticals
Cytokine Release Syndrome, Recurrent Multiple Myeloma
Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma
This phase II trial tests how well giving infliximab works for the prevention of cytokine release syndrome (CRS) during treatment with teclistamab or talquetamab in patients with multiple myeloma that has come back after a period…
- Conditions
- Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT07657312
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Naresh Bumma
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
INfections in Patients Treated With CAR-T
This study includes adults with multiple myeloma or B-cell lymphoma who were/will be treated with CAR-T cell therapy at the IRCCS Azienda Ospedaliero-Universitaria di Bologna.
- Conditions
- Relapsed Multiple Myeloma, Refractory Multiple Myeloma, B-Cell Non-Hodgkin Lymphoma, Bloodstream Infections
- Trial name
- IN-CART (NCT07713511)
- Where
- Italy
- Volunteers
- 290 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hemorrhagic Shock, Pelvic Fractures
Hemorrhagic Shock in Orthopedic Fractures
The goal of this observational study is to learn about the incidence and predators of hemorrhagic shock in patients with Long bone and pelvic fractures .The main question it aims to answer is: In which bone fracture the…
- Conditions
- Hemorrhagic Shock, Pelvic Fractures, Long Bone Fractures
- Trial name
- NCT07695129
- Where
- Egypt
- Volunteers
- 250 people
- Sponsor
- Sohag University